Literature DB >> 8361236

Lymphoproliferative disorders in an IL-7 transgenic mouse line.

A G Fisher1, C Burdet, M LeMeur, D Haasner, P Gerber, R Ceredig.   

Abstract

A high incidence of severe lymphoproliferative disease was observed in a newly generated strain of mice carrying murine IL-7 as a transgene under the control of the E alpha (MHC class II) promoter. An analysis of the cells from lesions in these mice shows the selective expansion of cells at an early stage of B cell development and, more interestingly, expansion of cells phenotypically identical to the recently reported bipotent (B/macrophage) stem cell populations described in midgestation embryonic liver. Such cells can be propagated (and remain dependent upon) bone marrow feeder cell lines obtained from IL-7 transgenic mice. A molecular analysis of fresh and cultured cells reveals that the lesions are oligoclonal, or in rare cases monoclonal, and include clones of cells with unrearranged Ig heavy chain loci. These data suggest that IL-7 acts at multiple stages of B cell development. Furthermore cell lines derived from IL-7 transgenic mice may provide a novel source of rare factor-dependent bipotent stem cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8361236

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

Review 1.  Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling.

Authors:  Sebastian Herzog; Michael Reth; Hassan Jumaa
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

2.  The interaction of LCK and the CD4 co-receptor alters the dose response of T-cells to interleukin-7.

Authors:  Christina Kittipatarin; Nuska Tschammer; Annette R Khaled
Journal:  Immunol Lett       Date:  2010-04-28       Impact factor: 3.685

Review 3.  Cell circuits and niches controlling B cell development.

Authors:  Sandra Zehentmeier; João P Pereira
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

4.  Permissive roles of cytokines interleukin-7 and Flt3 ligand in mouse B-cell lineage commitment.

Authors:  Lilly von Muenchow; Llucia Alberti-Servera; Fabian Klein; Giuseppina Capoferri; Daniela Finke; Rhodri Ceredig; Antonius Rolink; Panagiotis Tsapogas
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-29       Impact factor: 11.205

5.  BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.

Authors:  Joji Nakayama; Mutsumi Yamamoto; Katsuhiko Hayashi; Hitoshi Satoh; Kenji Bundo; Masato Kubo; Ryo Goitsuka; Michael A Farrar; Daisuke Kitamura
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

6.  IL-7 functionally segregates the pro-B cell stage by regulating transcription of recombination mediators across cell cycle.

Authors:  Kristen Johnson; Julie Chaumeil; Mariann Micsinai; Joy M H Wang; Laura B Ramsey; Gisele V Baracho; Robert C Rickert; Francesco Strino; Yuval Kluger; Michael A Farrar; Jane A Skok
Journal:  J Immunol       Date:  2012-05-11       Impact factor: 5.422

7.  Loss of Bim allows precursor B cell survival but not precursor B cell differentiation in the absence of interleukin 7.

Authors:  Paula M Oliver; Michael Wang; Yanan Zhu; Janice White; John Kappler; Philippa Marrack
Journal:  J Exp Med       Date:  2004-11-01       Impact factor: 14.307

8.  Restoration of Endogenous Retrovirus Infectivity Impacts Mouse Cancer Models.

Authors:  Eleonora Ottina; Prisca Levy; Urszula Eksmond; Julia Merkenschlager; George R Young; Juliette Roels; Jonathan P Stoye; Thomas Tüting; Dinis P Calado; George Kassiotis
Journal:  Cancer Immunol Res       Date:  2018-08-24       Impact factor: 11.151

9.  Accumulation of Multipotent Hematopoietic Progenitors in Peripheral Lymphoid Organs of Mice Over-expressing Interleukin-7 and Flt3-Ligand.

Authors:  Fabian Klein; Lilly von Muenchow; Giuseppina Capoferri; Stefan Heiler; Llucia Alberti-Servera; Hannie Rolink; Corinne Engdahl; Michael Rolink; Mladen Mitrovic; Grozdan Cvijetic; Jan Andersson; Rhodri Ceredig; Panagiotis Tsapogas; Antonius Rolink
Journal:  Front Immunol       Date:  2018-10-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.